Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00088452 |
|
Recruitment Status :
Completed
First Posted : July 27, 2004
Results First Posted : October 14, 2020
Last Update Posted : October 14, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Childhood Absence Epilepsy Petit Mal Epilepsy Epilepsy Seizures | Drug: Ethosuximide Drug: Lamotrigine Drug: Valproic acid | Phase 3 |
Childhood absence epilepsy (CAE) is a common pediatric epilepsy syndrome that affects 10 to 15 percent of all children with epilepsy. Individuals with CAE have brief staring spell seizures that occur suddenly, unpredictably, and frequently throughout the day. These seizures impair the children's ability to learn and play, and lead to higher injury rates.
There are many medications used to treat seizures, but only 3 generally are used as the first treatment for children with CAE: ethosuximide, lamotrigine, and valproic acid. The goal of this study is to determine which of these 3 medicines is the best first choice as treatment for children with CAE.
Approximately 439 children, recruited over a 3-year period at 32 medical centers in the US, will take part in this 5-year study. Participants will be randomly given one of the 3 common CAE treatments-ethosuximide, lamotrigine, or valproic acid-and will make regular visits to a clinic every 1 to 3 months for approximately 2 years. During the visits, participants will undergo regular testing to determine if the medicine is working, to watch for side effects, and to help researchers learn more about the responses to these medicines. In addition, researchers hope to develop methods that may be used in the future to help choose the best medicine for each individual diagnosed with CAE.
Also included in the study will be pharmacokinetics and pharmacogenetics research. Pharmacokinetics is the study of how the body absorbs, distributes, metabolizes, and excretes drugs. Pharmacogenetics is the study of genetic determinants of the response to drugs. Knowledge gained from this study may lead to individualized treatment for children with CAE, and may also be beneficial for other pediatric and adult seizure disorders.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 453 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study |
| Actual Study Start Date : | July 2004 |
| Actual Primary Completion Date : | January 2013 |
| Actual Study Completion Date : | August 31, 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Ethosuximide
Ethosuximide Frequency and Duration: twice a day, every day for the duration of the study treatment Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower) |
Drug: Ethosuximide
Ethosuximide is a common treatment for childhood absence epilepsy.
Other Name: Zarontin |
|
Active Comparator: Lamotrigine
Lamotrigine Frequency and Duration: twice a day, every day for the duration of the study treatment Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower). |
Drug: Lamotrigine
Lamotrigine is a common treatment for childhood absence epilepsy.
Other Name: Lamictal |
|
Active Comparator: Valproic acid
Valproic acid Frequency and Duration: twice a day, every day for the duration of the study treatment Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles. Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower) |
Drug: Valproic acid
Valproic acid is a common treatment for childhood absence epilepsy.
Other Name: Depakote |
- Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy [ Time Frame: First 16-20 weeks of double blind therapy ]Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.
- Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT [ Time Frame: First 16-20 weeks of double blind therapy ]A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder.
- Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy [ Time Frame: First 12 months of double blind therapy ]Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Months to 13 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Diagnosis: Clinical diagnosis of Childhood Absence Epilepsy consistent with the International League against Epilepsy Proposal for Revised Classification of Epilepsies and Epileptic Syndromes (3).
- EEG: Interictal EEG demonstrating bilateral synchronous symmetrical approximate 3 Hz spike waves on a normal background with at least one burst lasting >/= (greater than or equal to) 3 seconds.
- Age > 2.5 years and < 13 years of age at study entry.
- Body weight >/= (greater than or equal to) 10 kilograms.
- Body Mass Index: BMI for age =/< 99th percentile (based on the CDC BMI for age growth curves for boys/girls [http://www.cdc.gov/growthcharts], Appendix 1).
- Hepatic:
- AST/ALT < 2.5 times the upper limit of normal
- Total bilirubin < 1.5 times the upper limit of normal.
- Hematologic:
- Absolute neutrophil count >/= (greater than or equal to) 1500/mm3.
- Platelets >/= (greater than or equal to) 120, 000 /mm3.
- Female subjects must be premenarchal at the time of enrollment and must be willing to practice abstinence for the duration of the study.
- Parent/legal guardian(s) willing to sign an IRB approved informed consent.
- Subject assent (when appropriate and as dictated by local IRB).
Exclusion Criteria:
- Treatment for CAE with anti-seizure medications (AED) for a period of greater than 7 days prior to randomization.
- History of a major psychiatric disease (e.g., psychosis, major depression).
- History of autism or pervasive development disorder.
- History of non-febrile seizures other than typical absence seizures. This includes a history of an afebrile generalized tonic clonic seizure.
- Clinical signs and symptoms consistent with a diagnosis of juvenile absence epilepsy or juvenile myoclonic epilepsy as delineated by the International League against Epilepsy Proposal for Revised Classification of Epilepsies and Epileptic Syndromes (3).
- History of recent or present significant or medical disease, i.e., cardiovascular, hepatic, renal, gynecologic, musculoskeletal, metabolic, or endocrine.
- History of a severe dermatologic reaction (e.g., Stevens Johnson, toxic epidermolysis necrosis) to medication.
- Subject or parent/legal guardian might not be reasonably expected to be compliant with or to complete the study.
- Participation in a trial of an investigational drug or device within 30 days prior to screening.
- Use of systemic contraceptive for any indication, including acne.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00088452
Show 31 study locations
| Principal Investigator: | Tracy A. Glauser, MD | Children's Hospital Medical Center, Cincinnati | |
| Principal Investigator: | Peter Adamson, MD | Children's Hospital of Philadelphia | |
| Principal Investigator: | Avital Cnaan, PhD | Children's National Research Institute |
Documents provided by Children's Hospital Medical Center, Cincinnati:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Children's Hospital Medical Center, Cincinnati |
| ClinicalTrials.gov Identifier: | NCT00088452 |
| Other Study ID Numbers: |
U01NS045911 ( U.S. NIH Grant/Contract ) U01NS045803 ( U.S. NIH Grant/Contract ) |
| First Posted: | July 27, 2004 Key Record Dates |
| Results First Posted: | October 14, 2020 |
| Last Update Posted: | October 14, 2020 |
| Last Verified: | February 2017 |
|
childhood absence epilepsy CAE petit mal epilepsy epilepsy |
seizures ethosuximide lamotrigine valproic acid |
|
Epilepsy Seizures Epilepsy, Absence Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Epilepsy, Generalized Epileptic Syndromes Lamotrigine Valproic Acid Ethosuximide Anticonvulsants Calcium Channel Blockers |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Sodium Channel Blockers Enzyme Inhibitors GABA Agents Neurotransmitter Agents Antimanic Agents |